Please login to the form below

Not currently logged in

Dr James Mond appointed chief medical and scientific officer of ADMA Biologics

Will lead development of RI-001 for primary immunodeficiency disease

US biotech ADMA Biologics has appointed Dr James Mond as its chief medical and scientific officer while the company looks to initiative a phase III study investigating its lead drug candidate for use in the treatment of primary immunodeficiency disease (PIDD).

Dr Mond will be responsible for strategy and advancing all the ADMA's research programme, including the development of RI-001 - a plasma-derived intravenous immune globulin that contains a wide array of antibodies that are obtained from different B-cell resources.

“Dr Mond brings an extensive record of academic and industry clinical and regulatory experience to ADMA, which will be invaluable as we initiate our upcoming phase III study,” said Adam Grossman, president and CEO of ADMA.

Before joining ADMA, Dr Mond was most recently exectuvie VP and chief scientific officer of Biosynexus where he directed all of the preclinical and clinical trial activities.

Previously, he worked as a consultant to Virion Systems, where he oversaw the development of a vaccine technology that the company licensed to GlaxoSmithKline (GSK).

These vaccines have been commercialized to prevent pneumococcal infections and meningococcal infections in children.

25th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...